Ferguson Tess, Gordon Barbara
Obstetrics and Gynecology, Idaho College of Osteopathic Medicine, Meridian, USA.
Nutrition and Dietetics, Idaho State University, Meridian, USA.
Cureus. 2025 Mar 31;17(3):e81527. doi: 10.7759/cureus.81527. eCollection 2025 Mar.
Herbal remedies have been a mainstay of medicine for thousands of years. This systematic literature review investigated the efficacy and safety of chamomile herbal products among peripartum or postpartum women. Four peer-reviewed databases were searched through June 2024. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol was implemented, and the quality of studies was assessed using Cochrane Risk-of-Bias Assessment tools. A total of 23 studies (16 clinical trials and seven observational studies involving 2,065 women from nine countries) were included in this review. The development of clinical practice recommendations on using chamomile products during pregnancy is not feasible based on the available evidence, indicating the need for randomized, double-blind placebo control studies with larger study populations and consistent study protocols (e.g., type and dosage of chamomile ingested). Limitations of this review include its small sample size and the inclusion of multiple studies by the same research teams; these findings likely reflect insights from the same cohorts of women. Some studies reported clinically significant findings that were not statistically significant. Thus, despite weak evidence supporting the efficacy and safety of chamomile usage during pregnancy, a provider might still share the potential benefits and risks of using chamomile products with patients who use or desire to use chamomile products.
数千年来，草药一直是医学的中流砥柱。这项系统性文献综述调查了洋甘菊草药产品在围产期或产后女性中的疗效和安全性。检索了四个同行评审数据库，截至2024年6月。采用了系统评价和Meta分析的首选报告项目（PRISMA）方案，并使用Cochrane偏倚风险评估工具评估研究质量。本综述共纳入23项研究（16项临床试验和7项观察性研究，涉及来自9个国家的2065名女性）。基于现有证据，制定关于孕期使用洋甘菊产品的临床实践建议是不可行的，这表明需要开展更大样本量且研究方案一致（如摄入洋甘菊的类型和剂量）的随机、双盲安慰剂对照研究。本综述的局限性包括样本量小以及同一研究团队纳入了多项研究；这些发现可能反映的是同一批女性群体的见解。一些研究报告了具有临床意义但无统计学意义的结果。因此，尽管支持孕期使用洋甘菊的疗效和安全性的证据薄弱，但医疗服务提供者仍可能与使用或希望使用洋甘菊产品的患者分享使用洋甘菊产品的潜在益处和风险。
